2016
Vincent T. DeVita on His New Book, "The Death of Cancer," and the Current State of Cancer Care.
DeVita V. Vincent T. DeVita on His New Book, "The Death of Cancer," and the Current State of Cancer Care. Oncology 2016, 30: 210. PMID: 26984212.Peer-Reviewed Original ResearchA CONVERSATION WITH VINCENT DEVITA, MD. No Truce Sought in Cancer War: 'We Want to Cure This Disease'.
DeVita V, Wehrwein P. A CONVERSATION WITH VINCENT DEVITA, MD. No Truce Sought in Cancer War: 'We Want to Cure This Disease'. Managed Care 2016, 25: 39-41. PMID: 26882628.Peer-Reviewed Original Research
2014
Clinical cancer research: the past, present and the future
DeVita VT, Eggermont AM, Hellman S, Kerr DJ. Clinical cancer research: the past, present and the future. Nature Reviews Clinical Oncology 2014, 11: 663-669. PMID: 25245981, DOI: 10.1038/nrclinonc.2014.153.Peer-Reviewed Original Research
2008
The era of personalized medicine: back to basics
Hutchinson L, DeVita V. The era of personalized medicine: back to basics. Nature Reviews Clinical Oncology 2008, 5: 623-623. PMID: 18957968, DOI: 10.1038/ncponc1253.Peer-Reviewed Original ResearchAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzamidesBiomarkers, TumorCarcinoma, Non-Small-Cell LungCetuximabClinical Trials as TopicColorectal NeoplasmsDrug Delivery SystemsDrug Resistance, NeoplasmGene TargetingGenes, erbB-1HumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveLung NeoplasmsPanitumumabPatient-Centered CarePiperazinesPyrimidinesTreatment OutcomeStrong inference
DeVita V. Strong inference. Nature Reviews Clinical Oncology 2008, 5: 177-177. PMID: 18376422, DOI: 10.1038/ncponc1094.Peer-Reviewed Original Research
2006
Let's return to the “belly bath”
DeVita V. Let's return to the “belly bath”. Nature Reviews Clinical Oncology 2006, 3: 405-405. PMID: 16894365, DOI: 10.1038/ncponc0568.Peer-Reviewed Original ResearchAntineoplastic AgentsFemaleHumansInfusions, ParenteralNeoplasm StagingNeoplasm, ResidualOvarian NeoplasmsThe concept of cure
DeVita V. The concept of cure. Nature Reviews Clinical Oncology 2006, 3: 59-59. PMID: 16462824, DOI: 10.1038/ncponc0422.Peer-Reviewed Original Research
2005
Herceptin: HERalding a new era in breast cancer care but at what cost?
Hutchinson L, DeVita V. Herceptin: HERalding a new era in breast cancer care but at what cost? Nature Reviews Clinical Oncology 2005, 2: 595-595. PMID: 16341094, DOI: 10.1038/ncponc0378.Peer-Reviewed Original ResearchShould the FDA be the doctor of last resort?
DeVita V. Should the FDA be the doctor of last resort? Nature Reviews Clinical Oncology 2005, 2: 423-423. PMID: 16264991, DOI: 10.1038/ncponc0292.Peer-Reviewed Original Research
2000
Therapeutic implications of the new biology.
DeVita V, Abou-Alfa G. Therapeutic implications of the new biology. The Cancer Journal 2000, 6 Suppl 2: s113-20. PMID: 10803824.Peer-Reviewed Original Research
1999
Hodgkin's disease and transplantation: a room with a (nontransplanter's) view.
Marshall N, DeVita V. Hodgkin's disease and transplantation: a room with a (nontransplanter's) view. Seminars In Oncology 1999, 26: 67-73. PMID: 10073563.Peer-Reviewed Original ResearchConceptsHigh-dose chemotherapyPeripheral blood stem-cellHodgkin's diseaseOverall survivalRefractory diseaseDisease-freeBone marrowPeripheral blood stem-cell supportGraft-versus-host disease prophylaxisManagement of refractory diseasePatients potential candidatesImprove disease-freePatients disease-freeFollow-up timeShort follow-up timeResponse to treatmentSalvage chemotherapyApproach to treatmentCombination chemotherapyDose intensityTransplant supportAllograft patientsInitial remissionRelapse rateDisease prophylaxis
1997
Late sequelae of treatment of Hodgkin's disease
DeVita V. Late sequelae of treatment of Hodgkin's disease. Current Opinion In Oncology 1997, 9: 428-431. PMID: 9327220, DOI: 10.1097/00001622-199709050-00006.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsFemaleFollow-Up StudiesHodgkin DiseaseHumansLeukemiaNeoplasms, Second PrimaryRadiotherapyConceptsHodgkin's diseaseEarly-stage Hodgkin's diseaseLow-dose radiotherapyStage Hodgkin's diseaseRadiation treatment fieldLate sequelaeSecond malignanciesCombination chemotherapySuccessful treatmentClinical trialsFull dosesBreast cancerLeukemia riskSolid tumorsLow dosesYoung womenDiseaseChemotherapyTreatmentDosesTreatment fieldEarlier reportsRiskYearsReport
1996
Oncology
DeVita V, Deisseroth A. Oncology. JAMA 1996, 275: 1833-1834. PMID: 8642736, DOI: 10.1001/jama.1996.03530470061036.Peer-Reviewed Original Research
1995
The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents.
Deisseroth A, DeVita V. The cell cycle: Probing new molecular determinants of resistance and sensitivity to cytotoxic agents. The Cancer Journal 1995, 1: 15-21. PMID: 9166447.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsCell CycleDrug Resistance, NeoplasmHumansModels, BiologicalNeoplasmsTumor Suppressor Protein p53ConceptsMolecular determinants of resistanceNormal tissuesSensitivity to cytotoxic agentsConventional dose therapyTherapy-induced side effectsIntroduction of chemotherapyCurative therapeutic interventionParadigm of treatmentPresence of mutationsCells to treatmentDose therapyBiologic therapySolid tumorsDeterminants of resistanceHematopoietic neoplasmsChemotherapeutic agentsChemotherapyCytotoxic agentsNeoplastic cellsSide effectsTherapyApplication of molecular analysisTherapeutic interventionsCell deathNeoplasms
1990
Primary Chemotherapy Can Avoid Mastectomy, but There Is More to It Than That
DeVita V. Primary Chemotherapy Can Avoid Mastectomy, but There Is More to It Than That. Journal Of The National Cancer Institute 1990, 82: 1528-1528. PMID: 2205725, DOI: 10.1093/jnci/82.19.1528.Peer-Reviewed Original Research
1988
Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities.
Whang-Peng J, Young R, Lee E, Longo D, Schechter G, DeVita V. Cytogenetic studies in patients with secondary leukemia/dysmyelopoietic syndrome after different treatment modalities. Blood 1988, 71: 403-14. PMID: 3337904, DOI: 10.1182/blood.v71.2.403.bloodjournal712403.Peer-Reviewed Original ResearchConceptsChromosomal abnormalitiesStructural abnormalitiesLoss of chromosome 7Cytogenetic studiesDe novo leukemiaCytogenetic abnormalitiesRadiation therapyExtensive chemotherapyNumerical abnormalitiesTreatment modalitiesSerial studiesChemotherapyPatientsAbnormalitiesTreatment groupsHematological changesChromosome 7SyndromeTreatmentChromosome 3HypodiploidyLeukemiaAneuploidyTherapy
1984
Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports.
DeVita V. Contrasting viewpoints on cancer drug development: the Wooldridge and Richardson reports. Journal Of The National Cancer Institute 1984, 68: 339-40. PMID: 6692433.Peer-Reviewed Original Research
1983
Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma.
Greene M, Young R, Merrill J, DeVita V. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Research 1983, 43: 1891-8. PMID: 6572558.Peer-Reviewed Original ResearchConceptsRisk of acute nonlymphocytic leukemiaNon-Hodgkin's lymphomaAcute nonlymphocytic leukemiaCases of acute nonlymphocytic leukemiaNonlymphocytic leukemiaTherapy of non-Hodgkin's lymphomaNon-Hodgkin lymphoma cohortNon-Hodgkin's lymphoma patientsSingle-modality therapyModel of leukemogenesisCase-control studyCumulative radiation dosePatients per yearOptimum patient managementHemibody radiationLeukemogenic therapyNational Cancer InstituteChemotherapy durationHistological subtypesChemotherapy doseTreatment regimensBone marrowTotal bodyPatient managementTherapyDiffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphomaThe cure of Hodgkin's disease with drugs.
DeVita V, Hubbard S, Moxley J. The cure of Hodgkin's disease with drugs. Advances In Internal Medicine 1983, 28: 277-302. PMID: 6188346.Peer-Reviewed Original Research